

Oklahoma Health Care Authority

Drug Utilization Review Board (DUR Board)

Meeting – March 13, 2019 @ 4:00pm

Oklahoma Health Care Authority
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call to Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. February 13, 2019 DUR Minutes – Vote
- B. February 13, 2019 DUR Recommendations Memorandum
- C. Correspondence

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on Medication Coverage Authorization Unit/Update: Drug Utilization Review of Prenatal Vitamins (PV) – See Appendix B

- A. Medication Coverage Activity for February 2019
- B. Pharmacy Helpdesk Activity for February 2019
- C. Update: Drug Utilization Review of Prenatal Vitamins (PV)

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Inbrija™ (Levodopa Inhalation) and Osmolex ER™ [Amantadine Extended-Release (ER)] – See Appendix C

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Abbott, Dr. Muchmore, Chairman:

6. Action Item – Vote to Prior Authorize Aimovig™ (Erenumab-aooe), Ajovy™ (Fremanezumab-vfrm), and Emgality® (Galcanzumab-gnlm) – See Appendix D

- A. Introduction
- B. Cost Comparison
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

7. Action Item – Vote to Prior Authorize Epidiolex® (Cannabidiol), Diacomit® (Stiripentol), and Sympazan™ (Clobazam Oral Film) – See Appendix E

- A. Introduction
- B. Market News and Updates
- C. College of Pharmacy Recommendations

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

8. Action Item – Vote to Prior Authorize Gamifant® (Emapalumab-lzsg) – See Appendix F

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

9. Action Item – Vote to Prior Authorize Firdapse® (Amifampridine) – See Appendix G

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

10. Action Item – Vote to Prior Authorize Retacrit™ (Epoetin Alfa-epbx) – See Appendix H

- A. Introduction
- B. College of Pharmacy Recommendations

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

11. Annual Review of Chronic Lymphocytic Leukemia (CLL) Medications and 30-Day Notice to Prior Authorize Copiktra™ (Duvelisib) – See Appendix I

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of CLL Medications
- D. Prior Authorization of CLL Medications
- E. Market News and Updates
- F. Copiktra™ (Duvelisib) Product Summary
- G. Recommendations
- H. Utilization Details of CLL Medications

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

12. Annual Review of Lymphoma Medications and 30-Day Notice to Prior Authorize Adcetris® (Brentuximab Vedotin), Beleodaq® (Belinostat), Calquence® (Acalabrutinib), Foltyn® (Pralatrexate), Istodax® (Romidepsin), Poteligeo® (Mogamulizumab-kpkc), Truxima® (Rituximab-abbs), Zevalin® (Ibritumomab Tiuxetan), and Zolinza® (Vorinostat) – See Appendix J

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Lymphoma Medications
- D. Prior Authorization of Lymphoma Medications
- E. Market News and Updates
- F. Product Summaries
- G. Recommendations
- H. Utilization Details of Lymphoma Medications

Items to be presented by Dr. Schmidt, Dr. Borders, Dr. Medina, Dr. Muchmore, Chairman:

13. 30-Day Notice to Prior Authorize Lutathera® (Lutetium Lu 177 Dotatate) and Vitrakvi® (Larotrectinib) – See Appendix K

- A. Introduction
- B. Market News and Updates
- C. Product Summaries
- D. Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman:

14. Action Item – Annual Review of Anticoagulants and Platelet Aggregation Inhibitors – See Appendix L

- A. Current Prior Authorization Criteria
- B. Utilization of Anticoagulants and Platelet Aggregation Inhibitors
- C. Prior Authorization of Anticoagulants and Platelet Aggregation Inhibitors
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Anticoagulants
- G. Utilization Details of Platelet Aggregation Inhibitors

Items to be presented by Dr. Chandler, Dr. Muchmore, Chairman:

15. Annual Review of Hereditary Angioedema (HAE) Medications and 30-Day Notice to Prior Authorize Takhzyro™ (Lanadelumab-flyo) and to Update the Prior Authorization Criteria for Cinryze® (C1 Esterase Inhibitor), Haegarda® (C1 Esterase Inhibitor), and Kalbitor® (Ecallantide) – See Appendix M

- A. Current Prior Authorization Criteria
- B. Utilization of HAE Medications
- C. Prior Authorization of HAE Medications
- D. Market News and Updates
- E. Takhzyro™ (Lanadelumab-flyo) Product Summary
- F. College of Pharmacy Recommendations
- G. Utilization Details of HAE Medications

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

16. Annual Review of Multiple Sclerosis (MS) Medications – See Appendix N

- A. Current Prior Authorization Criteria
- B. Utilization of MS Medications
- C. Prior Authorization of MS Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of MS Medications

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

17. Annual Review of Luxturna™ (Voretigene Neparvovec-rzyl) – See Appendix O

- A. Introduction
- B. Current Prior Authorization Criteria
- C. Utilization of Luxturna™ (Voretigene Neparvovec-rzyl)
- D. Prior Authorization of Luxturna™ (Voretigene Neparvovec-rzyl)
- E. Market News and Updates
- F. College of Pharmacy Recommendations

Items to be presented by Dr. Connell, Dr. Muchmore, Chairman:

18. Annual Review of Osteoporosis Medications – See Appendix P

- A. Current Prior Authorization Criteria
- B. Utilization of Osteoporosis Medications
- C. Prior Authorization of Osteoporosis Medications
- D. Market News and Updates
- E. College of Pharmacy Recommendations
- F. Utilization Details of Osteoporosis Medications

Non-Presentation; Questions Only:

19. Industry News and Updates – See Appendix Q

- A. Introduction
- B. News and Updates

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman:

20. U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix R

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

21. Future Business* (Upcoming Product and Class Reviews)

- A. Annual Review of Pharmacy Benefit
- B. Diabetic Medications
- C. Antihypertensive Medications
- D. Lung Cancer Medications
- E. Granulocyte Colony-Stimulating Factors

**Future business subject to change.*